Targeting intermediates of the PRMT5/BRG1 axis as a combination therapy

被引：0
|
作者：
Shaykevich, Aaron
Silverman, Isaac
Siegman, Alexander
Maitra, Radhashree
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1651
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia
    Jin, Yanli
    Zhou, Jingfeng
    Xu, Fang
    Jin, Bei
    Cui, Lijing
    Wang, Yun
    Du, Xin
    Li, Juan
    Li, Peng
    Ren, Ruibao
    Pan, Jingxuan
    JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (10): : 3961 - 3980
  • [32] RioK1, a New Interactor of Protein Arginine Methyltransferase 5 (PRMT5), Competes with pICln for Binding and Modulates PRMT5 Complex Composition and Substrate Specificity
    Guderian, Gernot
    Peter, Christoph
    Wiesner, Julia
    Sickmann, Albert
    Schulze-Osthoff, Klaus
    Fischer, Utz
    Grimmler, Matthias
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (03) : 1976 - 1986
  • [33] LKB1 regulates PRMT5 activity in breast cancer
    Lattouf, Hanine
    Kassem, Loay
    Jacquemetton, Julien
    Choucair, Ali
    Poulard, Coralie
    Tredan, Olivier
    Corbo, Laura
    Diab-Assaf, Mona
    Hussein, Nader
    Treilleux, Isabelle
    Le Romancer, Muriel
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (03) : 595 - 606
  • [34] An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth
    Liu, Liu
    Yan, Hui
    Ruan, Maomei
    Yang, Hao
    Wang, Lihua
    Lei, Bei
    Sun, Xiaoyan
    Chang, Cheng
    Huang, Gang
    Xie, Wenhui
    CANCER SCIENCE, 2021, 112 (08) : 3083 - 3098
  • [35] PRMT1 and PRMT5: on the road of homologous recombination and non-homologous end joining
    Shasha Yin
    Liu Liu
    Wenjian Gan
    Genome Instability & Disease, 2023, 4 (4) : 197 - 209
  • [36] PRMT5 facilitates angiogenesis and EMT via HIF-1α/VEGFR/Akt signaling axis in lung cancer
    Zheng, Yonghua
    Ji, Huaxia
    Yi, Wulin
    Chen, Zhanjun
    Hu, Xiaobiao
    Zhou, Jie
    Wang, Yang
    Zheng, Xiao
    AGING-US, 2023, 15 (13): : 6163 - 6178
  • [37] PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
    Berlin, Michael
    Cantley, Jennifer
    Bookbinder, Mark
    Bortolon, Elizabeth
    Broccatelli, Fabio
    Cadelina, Greg
    Chan, Emily W.
    Chen, Huifen
    Chen, Xin
    Cheng, Yunxing
    Cheung, Tommy K.
    Davenport, Kim
    DiNicola, Dean
    Gordon, Debbie
    Hamman, Brian D.
    Harbin, Alicia
    Haskell, Roy
    He, Mingtao
    Hole, Alison J.
    Januario, Thomas
    Kerry, Philip S.
    Koenig, Stefan G.
    Li, Limei
    Merchant, Mark
    Perez-Dorado, Inmaculada
    Pizzano, Jennifer
    Quinn, Connor
    Rose, Christopher M.
    Rousseau, Emma
    Soto, Leofal
    Staben, Leanna R.
    Sun, Hongming
    Tian, Qingping
    Wang, Jing
    Wang, Weifeng
    Ye, Crystal S.
    Ye, Xiaofen
    Zhang, Penghong
    Zhou, Yuhui
    Yauch, Robert
    Dragovich, Peter S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (02) : 1262 - 1313
  • [38] Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/ HER2 Inhibitors in Triple-Negative Breast Cancers
    Dakroub, Rayan
    Huard, Solane
    Hajj-Younes, Yara
    Suresh, Samyuktha
    Badran, Bassam
    Fayyad-Kazan, Hussein
    Dubois, Thierry
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 785 - 799
  • [39] Simultaneous targeting of LSD1 and PRMT5 through chimeric inhibitors as a novel therapeutic approach against leukemia
    Fiorentino, F.
    Pignata, L.
    Arceci, E.
    Di Bello, E.
    Bonaldi, T.
    Barone, M.
    Madl, T.
    Jeyasekharan, A.
    Mattevi, A.
    Valente, S.
    Guccione, E.
    Mai, A.
    FEBS OPEN BIO, 2024, 14 : 18 - 19
  • [40] The Methyltransferases PRMT4/CARM1 and PRMT5 Control Differentially Myogenesis in Zebrafish
    Batut, Julie
    Duboe, Carine
    Vandel, Laurence
    PLOS ONE, 2011, 6 (10):
12345